Investing.com - Insmed (NASDAQ: INSM) reported third quarter EPS of $-1.27, $0.07 worse than the analyst estimate of $-1.20. Revenue for the quarter came in at $93.42M versus the consensus estimate of $93.35M.
Guidance
Insmed sees FY 2024 revenue of $340.00M-$360.00M versus the analyst consensus of $357.10M.
Insmed's stock price closed at $70.30. It is down -2.10% in the last 3 months and up 181.31% in the last 12 months.
Insmed saw 0 positive EPS revisions and 9 negative EPS revisions in the last 90 days. See Insmed's stock price’s past reactions to earnings here.
According to InvestingPro, Insmed's Financial Health score is "fair performance".
Check out Insmed's recent earnings performance, and Insmed's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar